Compare Dow Inc (DOW) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Incyte Corporation — how do they compare? Dow Inc trades at $30.76 (market cap $22.58B), while Incyte Corporation trades at $121.12 (market cap $24.54B). The key difference: Dow Inc and Incyte Corporation are close in size by market cap, and Dow Inc pays a 4.48% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| DOW | INCY | |
|---|---|---|
Market Cap | $22.58B | $24.54B |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $129.93 |
52-Week Low | $20.65 | $81.61 |
Enterprise Value | $38.27B | $20.04B |
Dividend Yield | 4.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $30.78, up 0.65% today, with a bullish technical signal and positive earnings beats in recent quarters. However, the company reported a net loss of $2.62 billion in 2025, with declining revenue and negative profit margins. Analyst consensus is a 'Hold' with a $35.11 price target, suggesting modest upside potential from current levels.
The outlook is mixed; earnings improvements and dividend payments provide support, but persistent losses and high debt pose risks. Investment opportunity hinges on a turnaround in profitability, while key risks include competitive pressures and macroeconomic headwinds affecting the chemicals sector.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
